Citations

Mayo Clinic

Showing 10 of 108599 citations.

Longitudinal Study of Pediatric Urticaria Pigmentosa
Heinze, Adam , Kuemmet, Travis J., Chiu, Yvonne E. , Galbraith, Sheila S., Chiu, Yvonne E

Pediatric Dermatology | January 30, 2017 | Volume: 34 | Issue: 2 | Pages: 144-149

10.1111/pde.13066 | PMID 28133781 Get It

AbstractBackground/ObjectivesUrticaria pigmentosa (UP) is the most common form of mastocytosis in children and is associated with systemic signs, symptoms, and triggers. To our knowledge, the effect of UP on children's quality of life has not been studied. The objective of the current study was to characterize the natural history, triggers, and complications of pediatric UP, identify prognostic indicators, and determine its effect on quality of life.MethodsBetween 2002 and 2007, children with three or more mastocytomas diagnosed by a pediatric dermatologist were recruited during visits at the Children's Hospital of Wisconsin Dermatology Clinic (Milwaukee, WI). Research visits were conducted every 3 years and telephone interviews yearly. The Children's Dermatology Life Quality Index was administered to subjects 4 years of age and older at enrollment. Laboratory test results were collected for subjects younger than 4 years at enrollment. Subjects were followed until UP resolution or study end in August 2015.ResultsThe final cohort size was 43 subjects followed for a median of 8.1 years. Twenty‐six subjects were followed through study completion. At age 12 years, 6 patients had disease resolution and 14 remained active. Patients who had disease resolution before age 12 years were more likely to be male and had fewer years of age and smaller lesions, fewer affected areas, and earlier onset. Common medications and anesthetics resulted in no serious reactions. Hymenoptera stings occurred in 51%, with no reports of anaphylaxis. No patient reported a severe effect on quality of life, with most indicating mild to no effect.ConclusionSevere complications are not common with historically identified triggers. Disease does not resolve before adolescence in most children. UP has a minimal effect on quality of life for most children.
Identification of the Anterolateral Ligament on Magnetic Resonance Imaging
Patel, Karan A. , Chhabra, Anikar , Goodwin, Jill A., Hartigan, David E. , Patel, Karan , Chhabra, Anikar

Arthroscopy Techniques | January 30, 2017 | Volume: 6 | Issue: 1 | Pages: No page available

10.1016/j.eats.2016.09.015 | PMID 28373952 Get It

Abstract Studies continue to demonstrate the importance of the anterolateral ligament (ALL) as a secondary restraint in rotational stability of the knee. No clinical exam exists to reliably test the ALL. Advanced imaging allows the surgeon to reliably identify the ALL as an independent structure of the lateral knee. This technique paper provides a reproducible method for identification of the ALL on 3T magnetic resonance imaging based on previously conducted cadaveric dissections of the ligament. Technique Video video See video under supplementary data.
A Randomized, Double‐Blind Trial of Abatacept (CTLA‐4Ig) for the Treatment of Giant Cell Arteritis
Langford, Carol A. , Cuthbertson, David , Ytterberg, Steven R. , Carette, Simon , Seo, Philip , Moreland, Larry W. , Weisman, Michael, Koening, Curry L. , Sreih, Antoine G. , McAlear, Carol A. , Warrington, Kenneth J. , McKinnon, Kathleen, Forbess, Lindsy, Hoffman, Gary S., Borchin, Renée , Krischer, Jeffrey P. , Khalidi, Nader , Monach, Paul A. , Spiera, Robert , Pagnoux, Christian , Merkel, Peter A. , Moreland, Larry W , Warrington, Kenneth J

Arthritis & Rheumatology | January 30, 2017 | Volume: 69 | Issue: 4 | Pages: 837-845

10.1002/art.40044 | PMID 28133925 Get It

ObjectiveTo compare the efficacy of abatacept to that of placebo for the treatment of giant cell arteritis (GCA).MethodsIn this multicenter trial, patients with newly diagnosed or relapsing GCA were treated with abatacept 10 mg/kg intravenously on days 1, 15, and 29 and week 8, together with prednisone administered daily. At week 12, patients in remission underwent a double‐blinded randomization to continue to receive abatacept monthly or switch to placebo. Patients in both study arms received a standardized prednisone taper, with discontinuation of prednisone at week 28. All patients remained on their randomized assignment until meeting criteria for early termination or until 12 months after enrollment of the last patient. The primary end point was duration of remission (relapse‐free survival rate).ResultsForty‐nine eligible patients with GCA were enrolled and treated with prednisone and abatacept; of these, 41 reached the week 12 randomization and underwent a blinded randomization to receive abatacept or placebo. Prednisone was tapered using a standardized schedule, reaching a daily dosage of 20 mg at week 12 with discontinuation in all patients at week 28. The relapse‐free survival rate at 12 months was 48% for those receiving abatacept and 31% for those receiving placebo (P = 0.049). A longer median duration of remission was seen in those receiving abatacept compared to those receiving placebo (median duration 9.9 months versus 3.9 months; P = 0.023). There was no difference in the frequency or severity of adverse events, including infection, between the treatment arms.ConclusionIn patients with GCA, the addition of abatacept to a treatment regimen with prednisone reduced the risk of relapse and was not associated with a higher rate of toxicity compared to prednisone alone.
A Randomized, Double‐Blind Trial of Abatacept (CTLA‐4Ig) for the Treatment of Takayasu Arteritis
Langford, Carol A. , Cuthbertson, David , Ytterberg, Steven R. , Carette, Simon , Seo, Philip , Moreland, Larry W. , Weisman, Michael, Koening, Curry L. , Sreih, Antoine G. , McAlear, Carol A. , Warrington, Kenneth J. , McKinnon, Kathleen, Forbess, Lindsy, Hoffman, Gary S., Borchin, Renée , Krischer, Jeffrey P. , Khalidi, Nader , Monach, Paul A. , Spiera, Robert , Pagnoux, Christian , Merkel, Peter A. , Moreland, Larry W , Warrington, Kenneth J

Arthritis & Rheumatology | January 30, 2017 | Volume: 69 | Issue: 4 | Pages: 846-853

10.1002/art.40037 | PMID 28133931 Get It

Objective To compare the efficacy of abatacept to that of placebo for the treatment of Takayasu arteritis (TAK). Methods In this multicenter trial, patients with newly diagnosed or relapsing TAK were treated with abatacept 10 mg/kg intravenously on days 1, 15, and 29 and week 8, together with prednisone administered daily. At week 12, patients in remission underwent a double‐blinded randomization to continue to receive abatacept monthly or switch to placebo. Patients in both study arms received a standardized prednisone taper, reaching a dosage of 20 mg daily at week 12, with discontinuation of prednisone at week 28. All patients remained on their randomized assignment until meeting criteria for early termination or until 12 months after enrollment of the last patient. The primary end point was duration of remission (relapse‐free survival). Results Thirty‐four eligible patients with TAK were enrolled and treated with prednisone and abatacept; of these, 26 reached the week 12 randomization and underwent a blinded randomization to receive either abatacept or placebo. The relapse‐free survival rate at 12 months was 22% for those receiving abatacept and 40% for those receiving placebo ( P = 0.853). Treatment with abatacept in patients with TAK enrolled in this study was not associated with a longer median duration of remission (median duration 5.5 months for abatacept versus 5.7 months for placebo). There was no difference in the frequency or severity of adverse events, including infection, between the treatment arms. Conclusion In patients with TAK, the addition of abatacept to a treatment regimen with prednisone did not reduce the risk of relapse.
Single‐institution experience of radioembolization with yttrium‐90 microspheres for unresectable metastatic neuroendocrine liver tumors
Jia, Zhongzhi , Paz‐Fumagalli, Ricardo , Frey, G. , Sella, David M., McKinney, J. Mark , Wang, Weiping

Journal of Gastroenterology and Hepatology | January 29, 2017 | Volume: 32 | Issue: 9 | Pages: 1617-1623

10.1111/jgh.13752 | PMID 28132407 Get It

AbstractBackground and AimThe aim of this study was to assess the effectiveness of yttrium‐90 (90Y) microspheres for the treatment of unresectable metastatic liver neuroendocrine tumors (NET).MethodsFrom February 2006 to September 2015, 36 patients (19 male and 17 female, age 63.6 ± 9.4 years) who underwent 90Y therapy for unresectable liver metastases of NET were included and analyzed retrospectively. All patients received a variety of treatments before 90Y therapy. The radiological response, symptoms improvement of carcinoid syndrome, tumor marker changes, complications, side effects/toxicity, survival, and factors related to survival were evaluated and analyzed.ResultsOf the 36 patients, the mean delivered dose of 90Y was 1.8 ± 0.7 GBq with a total of 40 treatments. Overall disease control rate was 88.9% (32/36) at 3 months following therapy. In 16 patients with carcinoid syndrome, 15 (93.8%) patients had symptomatic improvement. Tumor marker response (5‐hydroxyindoleacetic acid [n = 7] and chromogranin A [n = 13]) at 3 months after treatment were as follows: none (n = 0, 4), partial (n = 6, 7), and complete (n = 1, 2). Radiation‐induced gastrointestinal ulcers (n = 2, 5.6%) were identified. Side effects included fatigue (n = 31, 86.1%), anorexia (n = 26, 72.2%), nausea (n = 15, 41.7%), vomiting (n = 14, 38.9%), abdominal pain (n = 10, 27.8%), and fever (n = 8, 22.2%). The mean follow‐up was 27.0 ± 16.4 months, with a median survival of 41.0 months. Child–Pugh classification (P = 0.008) and lymph node metastases (P = 0.045) had statistically significant influence on overall survival.ConclusionsYttrium‐90 radioembolization can be effective in the treatment of unresectable liver metastases of NET who failed to respond to other treatments.
Risk of Heart Failure With Preserved Ejection Fraction in Older Women After Contemporary Radiotherapy for Breast Cancer
Saiki, Hirofumi , Petersen, Ivy A. , Bailey, Kent R. , Finley, Randi R., Ruddy, Kathryn J. , Yan, Elizabeth , Redfield, Margaret M. , Dunlay, Shannon M. , Scott, Christopher G.

Circulation | January 29, 2017 | Volume: 135 | Issue: 15 | Pages: 1388-1396

10.1161/circulationaha.116.025434 | PMID 28132957 Get It

Background: Cardiomyocytes are resistant to radiation. However, cardiac radiation exposure causes coronary microvascular endothelial inflammation, a perturbation implicated in the pathogenesis of heart failure (HF) and particularly HF with preserved ejection fraction (HFpEF). Radiotherapy for breast cancer results in variable cardiac radiation exposure and may increase the risk of HF. Methods: We conducted a population-based case-control study of incident HF in 170 female residents of Olmsted County, Minnesota (59 cases and 111 controls), who underwent contemporary (1998–2013) radiotherapy for breast cancer with computed tomography–assisted radiotherapy planning. Controls were matched to cases for age, tumor side, chemotherapy use, diabetes mellitus, and hypertension. Mean cardiac radiation dose (MCRD) in each patient was calculated from the patient’s computed tomography images and radiotherapy plan. Results: Mean age at radiotherapy was 69±9 years. Of HF cases, 38 (64%) had EF≥50% (HFpEF), 18 (31%) had EF<50% (HF with reduced EF), and 3 (5%) did not have EF measured. The EF was ≥40% in 50 of the 56 HF cases (89%) with an EF measurement. The mean interval from radiotherapy to HF was 5.8±3.4 years. The odds of HF was higher in patients with a history of ischemic heart disease or atrial fibrillation. The MCRD was 2.5 Gy (range, 0.2–13.1 Gy) and higher in cases (3.3±2.7 Gy) than controls (2.1±2.0 Gy; P =0.004). The odds ratio (95% confidence interval) for HF per log MCRD was 9.1 (3.4–24.4) for any HF, 16.9 (3.9–73.7) for HFpEF, and 3.17 (0.8–13.0) for HF with reduced EF. The increased odds of any HF or HFpEF with increasing MCRD remained significant after adjustment for HF risk factors and in sensitivity analyses matching by cancer stage rather than tumor side. Only 18.6% of patients experienced new or recurrent ischemic events between radiotherapy and the onset of HF. Conclusions: The relative risk of HFpEF increases with increasing cardiac radiation exposure during contemporary conformal breast cancer radiotherapy. These data emphasize the importance of radiotherapy techniques that limit MCRD during breast cancer treatment. Moreover, these data provide further support for the importance of coronary microvascular compromise in the pathophysiology of HFpEF.
Effects of Surgical Factors on Cartilage Can Be Detected Using Quantitative Magnetic Resonance Imaging After Anterior Cruciate Ligament Reconstruction
Amano, Keiko , Li, Alan , Pedoia, Valentina , Krych, Aaron J. , Li, Xiaojuan , Benjamin, C. , Goldring, Steven R., Hannafin, Jo A., Marx, Robert G. , Nawabi, Danyal H. , Shah, Parina, Warren, Russell F. , Amrami, Kimberly K. , Felmlee, Joel P. , Frick, Matthew A., Williams, Steven L. , Kretzchmar, Martin, Okazaki, Narihiro , Russell, Colin, Savic, Dragana , Schwaiger, Benedikt J. , Cheong, Maxwell, Hardin, John , Koff, Matthew F. , Link, Thomas M. , Potter, Hollis G. , Rodeo, Scott A. , Majumdar, Sharmila , Goldring, Mary B. , Otero, Miguel , Stuart, Michael James , Lansdown, Drew Anderson , Russell, Colin, Su, Favian , Wyatt, Cory R. , Krych, Aaron J

The American Journal of Sports Medicine | January 28, 2017 | Volume: 45 | Issue: 5 | Pages: 1075-1084

10.1177/0363546516677794 | PMID 28768432 Get It

Background: Quantitative magnetic resonance (qMR) can be used to measure macromolecules in tissues and is a potential method of observing early cartilage changes in the development of posttraumatic osteoarthritis. Hypothesis/Purpose: We hypothesized that specific patient and surgical factors affecting cartilage matrix composition after anterior cruciate ligament (ACL) reconstruction (ACLR) can be detected using T1ρ and T2 relaxation times. Our purpose was to demonstrate this ability in a multicenter feasibility study. Study Design: Case series; Level of evidence, 4. Methods: A total of 54 patients who underwent ACLR underwent bilateral MRI at baseline before surgery and 6 months postoperatively. Operative findings were recorded. T1ρ and T2 relaxation times were calculated for 6 cartilage regions: the medial femur, lateral femur, medial tibia, lateral tibia, patella, and trochlea. A paired t test compared relaxation times at baseline and 6 months, univariate regression identified regions that influenced patient-reported outcome measures, and analysis of covariance was used to determine the surgical factors that resulted in elevated relaxation times at 6 months. Results: The injured knee had significantly prolonged T1ρ and T2 relaxation times in the tibiofemoral compartment at baseline and 6 months but had shorter values in the patellofemoral compartment compared with the uninjured knee. Prolonged T1ρ and T2 times at 6 months were noted for both the injured and uninjured knees. At 6 months, prolongation of T1ρ and T2 times in the tibial region was associated with lower patient-reported outcome measures. ACLR performed within 30 days of injury had significantly shorter T1ρ times in the tibial regions, and lateral meniscal tears treated with repair had significantly shorter T1ρ times than those treated with excision. Conclusion: Prolonged relaxation times in multiple regions demonstrate how the injury affects the entire joint after an ACL tear. Changes observed in the uninjured knee may be caused by increased loading during rehabilitation, especially in the patellofemoral articular cartilage and distal femur. Relaxation times in the tibial regions may be predictive of patient symptoms at 6 months. These same regions are affected by surgical timing as early as 30 days after injury, but this may partially be reflective of the severity of the preoperative injury and the choice of treatment of meniscal tears.
Granulocytic Sarcoma (Chloroma) of the Epiglottis
Ferguson, Jonathan L., Maragos, Nicolas E., Weiland, Louis H.

Otolaryngology–Head and Neck Surgery | January 28, 2017 | Volume: 97 | Issue: 6 | Pages: 588-590

10.1177/019459988709700613 | PMID 3124040 Get It

Study of Phonation in the Excised Canine Larynx
Yanagi, Eriko, Slavit, David H., McCaffrey, Thomas V.

Otolaryngology–Head and Neck Surgery | January 28, 2017 | Volume: 105 | Issue: 4 | Pages: 586-595

10.1177/019459989110500410 | PMID 1762795 Get It

Previous studies have demonstrated that the laryngeal muscles responsible for pitch variation and vocal efficiency are the cricothyroid muscles, affecting longitudinal tension of the vocal folds, and the thyroarytenoid muscles, controlling the lateral stiffness of the vocal folds. Longitudinal tension in the vocal fold is easily simulated in the excised canine larynx. The effect of the thyroarytenoid muscle, however, has not been adequately analyzed. To simulate the effect of the thyroarytenoid muscle, small balloons were placed in the paraglottic space at the level of the vocal folds in 10 excised canine laryngés. These balloons (Fogarty catheters) could be inflated in increments to simulate the effect of the thyroarytenoid muscle contraction in altering the lateral stiffness of the vocal fold. During phonation subglottic pressure, vocal fold longitudinal tension and balloon size were systematically varied. The photoglottographic and electroglottographic signals, sound intensity, and airflow rate were measured. Multiple regression analysis showed that sound intensity was directly related to subglottic pressure (p < 0.001) and inversely related to balloon size (p < 0.001). Vocal efficiency was directly related to subglottic pressure (p < 0.001). Frequency of vibration was directly related to balloon size (p < 0.05), vocal fold tension (p < 0.001), and subglottic pressure (p < 0.001). Open quotient was directly related to vocal fold tension (p < 0.01) and inversely related to balloon size (p < 0.001). Clinical implications of these results will be discussed.